Tag Archives: drug development

NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”

New York Times Building

Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the attention the cost has received to date, those attacking the drug are “looking at the costs of Sovaldi in the wrong way.” Sanger-Katz acknowledges that these one-time treatments can be a ‘shock to the system,’ but notes the value far outweighs the expense since it cures the disease in the majority of patients, preventing further costly treatments and care. Sanger-Katz Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotech Stocks: Perspective in a Bull Market

biotech companies

Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong earnings growth from large companies, and a more mature industry. Recent advancements in biotechnology are revolutionizing treatments and cures for many illnesses, creating new value for the healthcare system. In 2013, our understanding of how therapeutics can be used to harness the immune system to destroy cancer cells exploded with many companies reporting solid data in human testing. In 2014, Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

A Better Way to Make Unnatural Amino Acids Discovered by Yu

Make Unnatural Amino Acids

Certain amino acids that are not found in nature are highly sought after by pharmaceutical manufacturers. These “unnatural” amino acids have traditionally been very difficult to synthesize, so a new and improved technique for doing so is attracting a lot of attention. Amino acids are among the most basic components of living things. Long chains of them, translated from DNA, fold up to become proteins, some smaller groupings of amino acids form hormones, and a Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Making it Personal

making-it-personal copy

The “valley of death” between drug discovery and the development and provision of therapy is a huge issue in biotech. Recent news, however, highlights valiant entrepreneurs who look at the chasm and are building bridges to cross it. One of these is Ilan Ganot whose son, Eytani, was diagnosed with Duchenne muscular dystrophy (DMD) at the age of two years old. The ex-hedge fund banker at JPMorgan Chase & Co quit his job in London, Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Syringes for Clinical Trials

lab_tech02

Today’s pharmaceutical and biotechnology companies are under pressure to remain competitive. To do so, they require innovative approaches to manage drug development, particularly early development work. Any competitive advantage in the development process is highly prized – and one approach is to begin the development of the compound in a prefilled syringe earlier in the process, rather than later. Traditionally, biopharmaceutical companies have almost exclusively used vials in drug development. There are good reasons for Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,